Interim Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Millions |
3 Months Ended |
9 Months Ended |
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
| Income Statement [Abstract] |
|
|
|
|
|
| Net sales |
|
$ 1,398
|
$ 1,486
|
$ 4,078
|
$ 4,357
|
| Cost of goods sold |
|
1,056
|
1,222
|
3,267
|
3,615
|
| Gross profit |
|
342
|
264
|
811
|
742
|
| Selling, general and administrative expense |
|
148
|
157
|
454
|
481
|
| Research and development expense |
|
19
|
18
|
60
|
68
|
| Restructuring and asset related charges, net |
|
60
|
184
|
145
|
245
|
| Goodwill impairment |
|
0
|
25
|
0
|
25
|
| Total expenses |
|
227
|
384
|
659
|
819
|
| Equity in earnings of affiliates |
|
9
|
7
|
17
|
18
|
| Interest expense, net |
|
(51)
|
(51)
|
(157)
|
(79)
|
| Other income, net |
|
161
|
57
|
250
|
71
|
| Income (loss) before income taxes |
|
234
|
(107)
|
262
|
(67)
|
| Provision (benefit from) for income taxes |
|
30
|
(78)
|
25
|
(63)
|
| Net income (loss) |
|
204
|
(29)
|
237
|
(4)
|
| Less: Net income attributable to noncontrolling interests |
|
0
|
0
|
0
|
0
|
| Net income (loss) attributable to Chemours |
|
$ 204
|
$ (29)
|
$ 237
|
$ (4)
|
| Per share data |
|
|
|
|
|
| Basic earnings (loss) per share of common stock (USD per share) |
[1] |
$ 1.12
|
$ (0.16)
|
$ 1.31
|
$ (0.02)
|
| Diluted earnings per share of common stock (USD per share) |
[1] |
1.11
|
(0.16)
|
1.30
|
(0.02)
|
| Dividends per share of common stock (USD per share) |
[1] |
$ 0.03
|
$ 0.03
|
$ 0.09
|
$ 0.58
|
|
|